Cost Effectiveness Distribution of the Monte Carlo probabilistic sensitivity analysis for 12 key clinical and laboratory parameters after 100,000 iterations. The original values and calculation of incremental costs per healthy life year are shown
<p>Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strateg...
<p>Monte Carlo simulation results on cost-effectiveness plane for the expanded newborn screening sho...
<p>Cost effectiveness acceptability curve (CEAC) for the probabilistic sensitivity analysis for 10,0...
Cost Effectiveness Distribution of the Monte Carlo probabilistic sensitivity analysis for 12 key cli...
<p>The cost-effectiveness scatterplot shows incremental costs (€) versus incremental effectiveness e...
<p>Pre-PC period = baseline; <b>A)</b> Monte Carlo simulation sensitivity analysis for ratio of cost...
Values are presented in cost-effective planes of incremental costs ($ billions) versus incremental Q...
<p>The analysis uses 1,000 non-homogeneous Markov-Chain Monte Carlo simulations of 1,000 patients fo...
<p>Each point represents incremental cost (year 2013 values) and Quality adjusted life year gained (...
<p>A: cost-effectiveness plane; B: cost-effectiveness acceptability curve. ICER, incremental cost-ef...
Each dot represents the incremental health-related outcomes and costs of one sample (i.e., the popul...
<p>The scatterplots show the distribution of the incremental cost-effectiveness ratio for the differ...
Values are presented in cost-effectiveness planes of incremental costs ($ billions) versus increment...
<p>PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir...
<p>The figure shows the distribution of cost-effectiveness pairs on the cost-effectiveness plane.</p
<p>Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strateg...
<p>Monte Carlo simulation results on cost-effectiveness plane for the expanded newborn screening sho...
<p>Cost effectiveness acceptability curve (CEAC) for the probabilistic sensitivity analysis for 10,0...
Cost Effectiveness Distribution of the Monte Carlo probabilistic sensitivity analysis for 12 key cli...
<p>The cost-effectiveness scatterplot shows incremental costs (€) versus incremental effectiveness e...
<p>Pre-PC period = baseline; <b>A)</b> Monte Carlo simulation sensitivity analysis for ratio of cost...
Values are presented in cost-effective planes of incremental costs ($ billions) versus incremental Q...
<p>The analysis uses 1,000 non-homogeneous Markov-Chain Monte Carlo simulations of 1,000 patients fo...
<p>Each point represents incremental cost (year 2013 values) and Quality adjusted life year gained (...
<p>A: cost-effectiveness plane; B: cost-effectiveness acceptability curve. ICER, incremental cost-ef...
Each dot represents the incremental health-related outcomes and costs of one sample (i.e., the popul...
<p>The scatterplots show the distribution of the incremental cost-effectiveness ratio for the differ...
Values are presented in cost-effectiveness planes of incremental costs ($ billions) versus increment...
<p>PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir...
<p>The figure shows the distribution of cost-effectiveness pairs on the cost-effectiveness plane.</p
<p>Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strateg...
<p>Monte Carlo simulation results on cost-effectiveness plane for the expanded newborn screening sho...
<p>Cost effectiveness acceptability curve (CEAC) for the probabilistic sensitivity analysis for 10,0...
DOI
Add to ORKG